Chieh-I Chen Selected Research

sarilumab

11/2019	Cost-Effectiveness of Sarilumab Added to Methotrexate in the Treatment of Adult Patients with Moderately to Severely Active Rheumatoid Arthritis Who Have Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors.
10/2019	Effects of Sarilumab on Rheumatoid Arthritis as Reported by Patients Using the Rheumatoid Arthritis Impact of Disease Scale.
1/2019	Evaluation of the efficacy and safety of sarilumab combination therapy in patients with rheumatoid arthritis with inadequate response to conventional disease-modifying antirheumatic drugs or tumour necrosis factor α inhibitors: systematic literature review and network meta-analyses.
1/2019	Sarilumab monotherapy compared with adalimumab monotherapy for the treatment of moderately to severely active rheumatoid arthritis: an analysis of incremental cost per effectively treated patient.
1/2019	Economic Evaluation of Sarilumab in the Treatment of Adult Patients with Moderately-to-Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic Disease-Modifying Antirheumatic Drugs.
1/2019	Indirect Treatment Comparison of the Efficacy and Safety of Sarilumab Monotherapy in Rheumatoid Arthritis Patients with Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs.
1/2018	Budget impact analysis of sarilumab for the treatment of rheumatoid arthritis in patients with an inadequate response to conventional synthetic DMARD or TNF inhibitor therapies.
1/2018	Patient-reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis.
1/2017	Sarilumab improves patient-reported outcomes in rheumatoid arthritis patients with inadequate response/intolerance to tumour necrosis factor inhibitors.
1/2016	Sarilumab plus methotrexate improves patient-reported outcomes in patients with active rheumatoid arthritis and inadequate responses to methotrexate: results of a phase III trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Chieh-I Chen Research Topics

Disease

15	Rheumatoid Arthritis 11/2019 - 01/2016
5	Squamous Cell Carcinoma (Epidermoid Carcinoma) 11/2021 - 02/2020
5	Pain (Aches) 01/2021 - 02/2014
3	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2022 - 01/2021
3	Fatigue 01/2018 - 01/2016
2	Disease Progression 10/2022 - 01/2021
2	Infections 01/2019 - 01/2019
2	Necrosis 01/2019 - 01/2017
2	Chronic Disease (Chronic Diseases) 01/2018 - 01/2016
2	Pneumococcal Infections 07/2015 - 09/2014
1	Uterine Cervical Neoplasms (Cancer of the Cervix) 10/2022
1	Skin Neoplasms (Skin Cancer) 10/2022
1	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 01/2022
1	Rheumatic Diseases (Rheumatism) 01/2019
1	Human Influenza (Influenza) 07/2015
1	Healthcare-Associated Pneumonia 05/2014
1	Overactive Urinary Bladder (Overactive Bladder) 05/2014
1	Complex Regional Pain Syndromes 10/2008

Drug/Important Bio-Agent (IBA)

10	sarilumabIBA 11/2019 - 01/2016
9	cemiplimabIBA 10/2022 - 02/2020
8	Tumor Necrosis Factor InhibitorsIBA 11/2019 - 01/2016
8	Antirheumatic Agents (DMARD)IBA 01/2019 - 01/2016
5	Adalimumab (Humira)FDA Link 01/2019 - 01/2017
4	Methotrexate (Mexate)FDA LinkGeneric 11/2019 - 01/2016
4	ametantrone (HAQ)IBA 01/2019 - 01/2016
3	LigandsIBA 10/2022 - 01/2021
3	Abatacept (Orencia)FDA Link 06/2018 - 01/2017
3	golimumab FDA Link 06/2018 - 01/2017
3	tofacitinibIBA 06/2018 - 01/2017
3	Infliximab (Remicade)FDA Link 06/2018 - 01/2017
3	Etanercept (Enbrel)FDA Link 06/2018 - 01/2017
3	tocilizumab (atlizumab)FDA Link 06/2018 - 01/2017
3	Monoclonal AntibodiesIBA 01/2018 - 01/2017
2	PlatinumIBA 10/2022 - 01/2021
2	pembrolizumabIBA 01/2022 - 11/2021
2	Certolizumab Pegol FDA Link 05/2017 - 01/2017
1	B7-H1 AntigenIBA 01/2022
1	Chimeric Antigen ReceptorsIBA 01/2022
1	Biological ProductsIBA 01/2019
1	Interleukin-6 (Interleukin 6)IBA 06/2018
1	Janus Kinase InhibitorsIBA 06/2018
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 06/2018
1	Immunoglobulins (Immunoglobulin)IBA 01/2018
1	Interleukin-6 Receptors (Interleukin 6 Receptor)IBA 01/2018
1	Interleukin 1 Receptor Antagonist Protein (Anakinra)FDA Link 01/2017
1	Rituximab (Mabthera)FDA Link 01/2017
1	Pneumococcal Vaccines (Pneumococcal Polysaccharide Vaccine)IBA 07/2015
1	Heptavalent Pneumococcal Conjugate Vaccine (Prevnar)IBA 09/2014
1	Linezolid (Zyvox)FDA Link 05/2014
1	Vancomycin FDA LinkGeneric 05/2014
1	fesoterodine FDA Link 05/2014
1	Pharmaceutical PreparationsIBA 05/2014
1	Ibandronic Acid (Boniva)FDA Link 10/2008

Therapy/Procedure

8	Therapeutics 01/2022 - 01/2016
3	Drug Therapy (Chemotherapy) 10/2022 - 01/2021
1	Aftercare (After-Treatment) 01/2016
1	Incontinence Pads 02/2014